Poor
Not Aligned
Patient Risk:
Moderate
Summary
Many statements about liver injury incidence/rarity, symptom specifics, and management/alcohol guidance are not supported by the provided Lipitor prescribing information excerpts. The label excerpts only support that statins can cause biochemical liver function abnormalities, that persistent transaminase elevations can occur at an identified frequency, and that Lipitor should be used with caution in patients who consume substantial alcohol and/or have a history of liver disease.
Category Scores
Accurate Statements
Individual factors that can increase the risk of liver damage include existing liver disease.
Section 5.2:
A first sign of liver damage with these medicines can be higher liver blood tests, especially ALT and AST.
Section 5.2: statins associated with biochemical abnormalities of liver function and persistent elevations in serum transaminases.
Serious drug-induced liver injury is uncommon.
Section 5.2 provides a frequency for persistent transaminase elevations (0.7%), but does not explicitly equate this with 'serious drug-induced liver injury' being uncommon. (Partial support at best.)
Unsupported Statements
Lipitor (atorvastatin) can cause liver enzyme elevations in a small percentage of people.
Supported only in a limited way: Section 5.2 gives persistent elevations >3x ULN occurring in 0.7% of patients, but the claim is broader and does not specify the threshold/condition.
Serious liver injury from Lipitor (atorvastatin) is rare.
The provided excerpts do not state 'serious liver injury' rarity for atorvastatin.
Ibuprofen can also rarely cause liver injury.
No prescribing information excerpt for ibuprofen was provided; label support cannot be determined from the provided atorvastatin excerpts.
Both Lipitor (atorvastatin) and ibuprofen can be "liver-active" medications.
The provided Lipitor label excerpts do not use or support this characterization.
Taking Lipitor and ibuprofen at the same time does not automatically mean liver damage will occur.
No label support regarding combined use and likelihood of liver damage.
The risk of liver damage is usually driven more by individual factors than by the combination itself.
No label support regarding relative contribution of individual factors vs combination.
Individual factors that can increase the risk of liver damage include heavy alcohol use.
Section 5.2 supports caution in patients who consume substantial quantities of alcohol, but does not describe this as a 'risk factor that can increase' liver damage in the way claimed.
Individual factors that can increase the risk of liver damage include older age.
Not mentioned in the provided Lipitor label excerpts.
Individual factors that can increase the risk of liver damage include taking multiple liver-stressing medications.
Not mentioned in the provided Lipitor label excerpts.
Individual factors that can increase the risk of liver damage include taking higher doses or using either medication for prolonged periods.
The provided excerpts do not support dose/prolonged-period risk characterization for liver injury (they only provide dosing ranges and myopathy-related dose considerations).
Individual factors that can increase the risk of liver damage include taking other medicines that can affect the liver.
Not supported in the provided Lipitor excerpts.
Individual factors that can increase the risk of liver damage include a past history of medication-related liver injury.
The provided excerpts mention caution in patients with a history of liver disease; they do not specifically mention a past history of medication-related liver injury as a listed factor.
Serious drug-induced liver injury is uncommon.
No explicit 'drug-induced liver injury' rarity statement is provided in the excerpted label text.
Drug-induced liver injury may present with jaundice (yellowing of the skin/eyes).
Not described in the provided Lipitor label excerpts.
Drug-induced liver injury may present with dark urine.
Not described in the provided Lipitor label excerpts.
Drug-induced liver injury may present with severe fatigue.
Not described in the provided Lipitor label excerpts.
Drug-induced liver injury may present with loss of appetite.
Not described in the provided Lipitor label excerpts.
Drug-induced liver injury may present with nausea/vomiting.
Not described in the provided Lipitor label excerpts.
Drug-induced liver injury may present with right upper belly pain.
Not described in the provided Lipitor label excerpts.
Drug-induced liver injury may present with itching.
Not described in the provided Lipitor label excerpts.
Clinicians typically check liver enzymes and bilirubin promptly if symptoms of liver injury occur.
The provided excerpts do not include guidance about checking bilirubin promptly or a general 'typically' recommendation.
Use of the lowest effective ibuprofen dose for the shortest time is recommended when taking ibuprofen for pain if worried about liver risk.
No ibuprofen labeling excerpt is provided; no atorvastatin label support for this recommendation.
Avoid alcohol while taking ibuprofen is recommended.
No ibuprofen labeling excerpt is provided; and the Lipitor excerpts only support caution in those who consume substantial quantities of alcohol, not an instruction to avoid alcohol with ibuprofen.
Contradictions
Low
AI Statement
Avoid alcohol while taking ibuprofen is recommended.
Label Reference
Section 5.2 only supports caution in patients who consume substantial quantities of alcohol and/or have a history of liver disease for statin use; it does not provide an 'avoid alcohol while taking ibuprofen' instruction.
Important Omissions
Risk characterization for hepatic transaminase elevations is specifically described in the label excerpt as persistent elevations (>3 times ULN) on 2 or more occasions occurring in 0.7% of patients; the response does not accurately constrain statements to this definition.
Importance:
Moderate
The label excerpt states 'Active liver disease' (including unexplained persistent elevations in hepatic transaminase levels) is a contraindication; the response does not mention this contraindication.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Several claims are not supported by the provided Lipitor prescribing information excerpts—particularly those involving ibuprofen and specific symptom patterns, plus management guidance. The only clearly label-supported elements here are that statins can be associated with biochemical liver function abnormalities, that persistent transaminase elevations occur (frequency given), and caution in patients who consume substantial alcohol and/or have a history of liver disease.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Major portions of the response introduce ibuprofen-specific and symptom/management details that are not supported by the provided atorvastatin FDA label excerpts, and several atorvastatin frequency/rarity statements are broader than the label data.
Suggested Improvement
Limit liver-related claims to the provided Lipitor label excerpts (biochemical liver function abnormalities; persistent transaminase elevations >3x ULN on 2+ occasions occurring in 0.7%; caution with substantial alcohol consumption and/or history of liver disease; active liver disease is a contraindication). Remove ibuprofen-specific assertions and nonspecific symptom/monitoring guidance not present in the label excerpts.